Paper
A sponsor can look ordinary on rate and still hold an enormous stock of unresolved years. Debt measures that chronic backlog directly.
Which named CT.gov sponsors accumulate the deepest unresolved overdue years once silence is measured beyond the two-year results deadline rather than by counts alone? We analysed 249,507 eligible older closed interventional studies from the March 29, 2026 full-registry snapshot. We summed unresolved years beyond the two-year mark for each named sponsor with at least 100 older studies and compared that debt with missing-results stock and mean unresolved age. GlaxoSmithKline carried the largest sponsor overdue-debt stock at 17,950 unresolved years, followed by Boehringer Ingelheim at 15,166 and National Cancer Institute at 14,020. Boehringer Ingelheim also carried the heaviest large-sponsor mean unresolved age at 17.7 years, while Sanofi and AstraZeneca remained debt holders on stock. Chronic CT.gov silence is not only how many studies remain overdue, but how long large sponsor portfolios stay unresolved after deadline. Overdue debt is a registry-timing measure based on time beyond the two-year mark and does not assign legal responsibility or explain delay.